Bionano Genomics, Inc.
BNGO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.01 | 0.01 |
| FCF Yield | -64.84% | -30.90% | -36.77% | -19.76% |
| EV / EBITDA | -1.57 | -6.29 | -42.49 | -2.89 |
| Quality | ||||
| ROIC | -14.86% | -11.98% | -12.68% | -18.97% |
| Gross Margin | 47.85% | 51.64% | 45.50% | 41.86% |
| Cash Conversion Ratio | 0.70 | 0.51 | 0.89 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.11% | -4.52% | -1.21% | 3.45% |
| Free Cash Flow Growth | -69.74% | -26.16% | 57.50% | 51.13% |
| Safety | ||||
| Net Debt / EBITDA | -0.50 | -3.69 | -28.17 | -1.03 |
| Interest Coverage | 0.00 | -106.85 | -99.59 | -442.26 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.38 | 0.32 | 0.43 |
| Cash Conversion Cycle | 80.10 | 112.73 | 135.19 | 131.50 |